Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB05 vs Synagis PK and Safety in Healthy Volunteers
NCT05121246Phase 1Completed
- Sponsor
- mAbxience
- Start
- Jun 2022
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of palivizumab biosimilar MB05 in respiratory syncytial virus infection (RSV) (3 arms), sponsored by mAbxience. Primary endpoints: Area Under the Serum Concentration Versus Time Curve From Time Zero to Infinity and Maximum Observed Serum Concentration. Started Jun 2022; status: completed.
02
Drugs
palivizumab biosimilar MB05
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05121246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05121246.